Jodie Wehling

Jodie Wehling is an accomplished biopharma executive with extensive experience in market access, trade, distribution, and contracting across various leading organizations. Currently serving as Vice President of Market Access at Mesoblast Limited since November 2019, Jodie is involved in the launch of the Allogeneic Cell Therapy Ryoncil. Previous roles include Vice President of Market Access at CARGO Therapeutics, where Jodie focused on global market access strategies for CARGO’s product candidates, and Principal Chief Executive Officer at Zamboni Access Consulting, specializing in innovative solutions for market access challenges in biotech. Jodie's experience also includes significant positions at Atara Bio, Celgene, and Johnson & Johnson, where Jodie successfully maximized formularies and negotiated profitable contracts, earning multiple accolades for performance and leadership. Educational background includes degrees from the University of Wisconsin, Madison, and The Wharton School.